University of Nebraska – Lincoln Institutional Biosafety Committee

Minutes of Regular IBC Meeting

Date: September 8, 2025

Location: Remote via Zoom
Call to Order: D. Loy called the meeting to order at 2:31 PM
Members Present: T. George (Community Member), K. Heath (Animal SME), A. Hilske (Plant SME), D. Loy (Chair), A. Mitra (Plant SME), K. O'Neil (Community Member), W. Niu (Member), N. Sexton (Member), D. Zinniel (Lab Rep)
Members Absent: H. Blair (BSO), D. Petrik (Community Member), M. Wiebe (Member)
Quorum Met: Yes
Ex-Officio Advisors: D. Hamernik, B. Osthus, R. Wenzl, S. Quinn
Others: R. Cederberg, L. Gregurek, A. Jungck, E. Schulz, K. Evans, Lauren Hauser
Review of Minutes from 8/11/2025 Meeting:
Motion to approve minutes made by A. Mitra, 2nd by D. Zinniel
Minutes approved unanimously as written.
For: 6
Against: 0
Abstained: 3
Declaration of Conflicts of Interest: D. Loy (103)

I. PUBLIC SESSION

A. Old Business:

1. Tabled Protocol registrations: None

2. Protocols with Contingencies Met:

NuRamp ID:	35
Form ID:	**26068**
TITLE:	**Genetic Improvement of Sorghum for Bioenergy, Feed, and Food Uses and Responses to Pathogens**
PI:	**Scott Sattler**
DEPT:	Department of Agronomy & Horticulture
Project Biosafety Level:	**BSL-2**
NIH Guidelines reference:	III-F-5, III-F-8, C-II, III-E, III-E-2, III-E-2-a
Date of IBC Review:	**7/14/2025**
IBC MOTION:	- Provide an updated pathogen inventory, confirm location and status of pathogens, and update permits
IBC ACTION:	***Adopted by voice vote***
PROTOCOL NOTES:	
Date of PI Response:	**8/21/2025**

PI Response:	Updated pathogen inventory (with location and status) and permits were uploaded.
Additional Comments:	None.

B. New Business:

1. New Protocol Registrations: None

2. Protocol Amendments:

NuRamp ID:	**1359**
Form ID:	**26176**
TITLE:	**Assessing the role of fatty acid metabolism in development of metabolic diseases.**
PI:	**Tomasz Bednarski**
DEPT:	Nutrition and Health Sciences
REVIEWED BY:	Full IBC Committee
Protocol Biosafety Level:	**BSL-2, ABSL-1 (Animal)**
NIH Guidelines reference:	III-F-8, C-I, C-VII, C-VIII, III-E-1, III-D-4-a (new)
IBC MOTION:	Approve with the following contingencies:
Contingencies/Issues:	• Staff completes required training
Made by:	N. Sexton
Seconded by:	K. Heath
IBC ACTION:	***Adopted by voice vote***
For:	7
Against:	0
Abstained:	2

PROTOCOL NOTES:	
Review of Protocol:	The IBC Chair provided an overview of the protocol and opened discussion to the committee.
Summary of Project(s):	Underlying molecular mechanisms of metabolic disease (MetS) are poorly understood. Evidence indicates that high intake of saturated fatty acids increases the risk of MetS in prospective studies, while a high intake of polyunsaturated fatty acids (PUFAs) reduces that risk. PUFAs are precursors for a plethora of signaling lipids and are critical for the regulation of membrane biophysical properties.
Changes to the Protocol:	Updated mouse cell lines, added a human cell line, AAV treatments, and added new NIH Guideline III-D-4-a. Title changed to reflect wider scope of work.
Risk Assessment Considerations:	
Genetic Material:	Metabolism genes
Vector system:	rAAV
Microbiological agents:	N/A

Organisms:	Updated mouse strains
OTCC:	Mouse organs, cell lines (mouse and human)
Toxins:	N/A
IRB protocol(s):	☐Yes ☑No **SROC protocol:** ☐Yes ☑No
IACUC Protocol(s):	☑Yes ☐No
Facility/Safety Summary:	The Committee reviewed the description of the facilities to be used and safety procedures and determined the facilities are appropriate for the proposed containment level and work to be conducted.
Safety Concerns:	None
Facility Concerns:	None
Vaccine/Medical Surveillance:	Hepatitis B vaccine
Administrative issues:	
Current safety training for staff:	Staff training deficiencies.
Current equipment certification:	Yes.
Date/Result of last EHS Survey:	Annual: 1/17/2025 — **Findings:** No findings.
IBC Discussion:	The committee had questions about whether the PI was using cell lines or organisms for AAV treatments, and the Assistant Biosafety Officer confirmed the PI is only currently using cell lines in the project. The Assistant Biosafety Officer explained that addition of new NIH guidelines is related to newly proposed work with AAV treatments in animals.

NuRamp ID:	**28**
Form ID:	**26175**
TITLE:	**UNL BPDF - Process Development and Pre-clinical Manufacturing of Recombinant Proteins**
PI:	**Scott Johnson**
DEPT:	Biological Process Development Facility
REVIEWED BY:	Full IBC Committee
Protocol Biosafety Level:	**BSL-1-LS (Large Scale)**
NIH Guidelines reference:	III-F-2, III-F-6, III-E, III-D-2-a, III-D-6
IBC MOTION:	Approve as written.
Contingencies/Issues:	• None
Made by:	K. Heath
Seconded by:	D. Zinniel
IBC ACTION:	***Adopted by voice vote***
For:	8
Against:	0
Abstained:	1

PROTOCOL NOTES:

Review of Protocol:	The IBC Chair provided an overview of the protocol and opened discussion to the committee.
Summary of Project(s):	This protocol covers all generic recombinant protein development and production projects where the product and/or process is designed for eventual use in human clinical trials or reagent use. Typically projects involve recombinant protein expression using a microbial system, i.e. yeast or E. coli systems and purification using conventional bioprocess techniques, i.e. column chromatography and tangential flow filtration, to produce a bulk drug substance with suitable quality to be used for human clinical trials.
Changes to the Protocol:	Added two new protein vaccines being expressed in E. coli with plasmid.
Risk Assessment Considerations:	
Genetic Material:	Malaria and Leishmania antigens
Vector system:	N/A
Microbiological agents:	N/A
Organisms:	N/A
OTCC:	N/A
Toxins:	N/A
IRB protocol(s):	☐Yes ☑No **SROC protocol:** ☐Yes ☑No
IACUC Protocol(s):	☐Yes ☑No
Facility/Safety Summary:	The Committee reviewed the description of the facilities to be used and safety procedures and determined the facilities are appropriate for the proposed containment level and work to be conducted.
Safety Concerns:	None
Facility Concerns:	None
Vaccine/Medical Surveillance:	None
Administrative issues:	
Current safety training for staff:	Yes.
Current equipment certification:	Yes.
Date/Result of last EHS Survey:	Annual / **Findings:** 2/14/2025 / All findings addressed.
IBC Discussion:	The committee had no concerns and determined the risk assessment to be similar to previously approved projects.

NuRamp ID:	**1341**
Form ID:	**26116**
TITLE:	**Strategies for Biological Agent Treatment Using Natural and Novel Materials**
PI:	**Eric Carnes**
DEPT:	Biological Systems Engineering

REVIEWED BY:	Full IBC Committee
Protocol Biosafety Level:	**BSL-2**
NIH Guidelines reference:	III-E, III-D-1-a, III-D-3-a
IBC MOTION:	Approve as written.
Contingencies/Issues:	• None
Made by:	D. Zinniel
Seconded by:	K. O'Neill
IBC ACTION:	***Adopted by voice vote***
For:	7
Against:	0
Abstained:	2

PROTOCOL NOTES:

Review of Protocol:	The IBC Chair provided an overview of the protocol and opened discussion to the committee.
Summary of Project(s):	Laboratory pursues several avenues to identify new strategies for biological agent treatment, including the isolation of bacteriophage from environmental samples and screening of phage and novel material effectiveness in inhibiting/controlling bacterial growth.
Changes to the Protocol:	Updated PI, Pathogenic Microorganisms and Biological Toxins lists, added new strains and removed animal work.
Risk Assessment Considerations:	
Genetic Material:	N/A
Vector system:	N/A
Microbiological agents:	Bacillus thuringiensis, Bacillus atrophaeus, Yersinia pestis (Harbin 35), Yersinia rohdei
Organisms:	N/A
OTCC:	N/A
Toxins:	N/A
IRB protocol(s):	☐Yes ☑No **SROC protocol:** ☐Yes ☑No
IACUC Protocol(s):	☐Yes ☑No
Facility/Safety Summary:	The Committee reviewed the description of the facilities to be used and safety procedures and determined the facilities are appropriate for the proposed containment level and work to be conducted.
Safety Concerns:	None
Facility Concerns:	None
Vaccine/Medical Surveillance:	None
Administrative issues:	
Current safety training for staff:	Yes.
Current equipment certification:	Yes.

Date/Result of last EHS Survey:	Annual	**Findings:**
	1/24/2025	No findings.

IBC Discussion:	Committee had questions about PI's updated pathogen inventory and wanted clarification that while the inventory list is long, only those pathogens listed in section III on the protocol are actually in use and the rest are in storage.

NuRamp ID:	**55**
Form ID:	**26061**
TITLE:	**Gene regulation and signaling in the fungal model organism Candida albicans and other yeasts**
PI:	**Kenneth Nickerson**
DEPT:	School of Biological Sciences
REVIEWED BY:	Full IBC Committee
Protocol Biosafety Level:	**BSL-2 (proposed)**
NIH Guidelines reference:	III-F-1, III-E, III-D-2-a
IBC MOTION:	Approve with the following contingencies:
Contingencies/Issues:	• Staff complete required training
Made by:	A.Mitra
Seconded by:	K. Heath
IBC ACTION:	***Adopted by voice vote***
For:	9
Against:	0
Abstained:	0

PROTOCOL NOTES:

Review of Protocol:	The IBC Chair provided an overview of the protocol and opened discussion to the committee.
Summary of Project(s):	Studying gene regulatory mechanisms by using two fungal model organisms, Candida albicans and Saccharomyces cerevisiae to understand how gene expression is regulated during cell and developmental biology.
Changes to the Protocol:	Updated title and pathogen inventory, new Candida strains, new gene targets, updated facilities, and updated containment from BSL-1 to BSL-2
Risk Assessment Considerations:	
Genetic Material:	Two new gene targets for cell regulation
Vector system:	N/A
Microbiological agents:	New Candida strains, adding clinical and drug-resistant strains from CDC collections.
Organisms:	N/A
OTCC:	N/A
Toxins:	N/A
IRB protocol(s):	☐Yes ☑No **SROC protocol:** ☐Yes ☑No
IACUC Protocol(s):	☐Yes ☑No
Facility/Safety Summary:	The Committee reviewed the description of the facilities to be used and safety procedures and determined the facilities are

	appropriate for the proposed containment level and work to be conducted.
Safety Concerns:	None
Facility Concerns:	None
Vaccine/Medical Surveillance:	None
Administrative issues:	
Current safety training for staff:	No.
Current equipment certification:	Yes.
Date/Result of last EHS Survey:	Annual: 4/16/2025 — **Findings:** Cloth chairs present in lab
IBC Discussion:	The committee had questions about whether facility changes were needed for the change in containment from BSL-1 to BSL-2. Assistant Biosafety Officer explained that PI is working in a space designed for BSL-2 work but the previous approval was for mutant *C. albicans* that had been considered RG1at its original approval. Lab is updating documentation to reflect *C. albicans* is currently RG2 and adding new clinical isolates that also require BSL-2 containment .

NuRamp ID:	**103**
Form ID:	**26160**
TITLE:	**Nebraska Veterinary Diagnostic Center IBC**
PI:	**Dustin Loy**
DEPT:	School of Veterinary Medicine and Biomedical Sciences
REVIEWED BY:	Full IBC Committee
Protocol Biosafety Level:	**BSL-2, ABSL-2 (Animal)**
NIH Guidelines reference:	III-F-1, III-F-2, III-E
IBC MOTION:	Approve as written.
Contingencies/Issues:	• None
Made by:	A. Mitra
Seconded by:	K. Heath
IBC ACTION:	***Adopted by voice vote***
For:	8
Against:	0
Abstained:	01
PROTOCOL NOTES:	
Review of Protocol:	A. Mitra provided an overview of the protocol and opened discussion to the committee.
Summary of Project(s):	The mission of the Veterinary Diagnostic Center (VDC) is the diagnosis, and/or surveillance and/or control of animal and potentially zoonotic diseases important to the livestock industries, animal health stakeholders, and citizens of the State of Nebraska.

Changes to the Protocol:	Added Bacillus anthracis Sterne (avirulent vaccine strain) as a control for PCR assay. Updated personnel. Condensed and clarified pathogen inventory. For clarity, potential pathogens that are tested for in samples were removed as agents and moved under RG-2 and RG-3 sample categories as they are not present in the lab. Updated prion disinfection section and clarified PPE. New USDA permit attached.
Risk Assessment Considerations:	
Genetic Material:	N/A
Vector system:	N/A
Microbiological agents:	Bacillus anthracis Sterne
Organisms:	N/A
OTCC:	N/A
Toxins:	N/A
IRB protocol(s):	☐Yes ☑No **SROC protocol:** ☐Yes ☑No
IACUC Protocol(s):	☐Yes ☑No
Facility/Safety Summary:	The Committee reviewed the description of the facilities to be used and safety procedures and determined the facilities are appropriate for the proposed containment level and work to be conducted.
Safety Concerns:	None
Facility Concerns:	None
Vaccine/Medical Surveillance:	None
Administrative issues:	
Current safety training for staff:	Yes.
Current equipment certification:	Yes.
Date/Result of last EHS Survey:	Annual: 10/21/2024 — **Findings:** All findings addressed.
IBC Discussion:	Committee asked PI how the live inactivated spore vaccine made from the Sterne strain would be used as an assay control. PI explained that one of the targets for the *B. anthracis* PCR assay is the toxin gene, DNA isolated from the vaccine is the control; bacteria is not being propagated.

3. Notice of NIH Exempt Protocol Approvals: None

4. Notice of Administratively Approved Amendments:

NuRamp ID:	950
Form ID:	**26179**
TITLE:	**Metabolomics Core Facility**

PI:	**Sophie Alvarez**
DEPT:	Center for Biotechnology
Project Biosafety Level:	BSL-2
NIH Guidelines reference:	III-F-8, C-I, C-VII
PROTOCOL NOTES:	
IRB protocol:	☐Yes ☑No **SROC protocol:** ☐Yes ☑No
IACUC Protocol:	☐Yes ☑No
Objective of Study:	Core facility used to analyze proteins and metabolites from a wide range of samples using mass spectrometry-based approaches.
Changes to the Protocol:	An additional sample preparation including a clean-up step for human plasma and urine samples was included in section II. Urine sample was added as a new sample to Section IV. Specialized equipment for the SPE was added to Section IX.
Review comments:	None.

NuRamp ID:	1126
Form ID:	**26156**
TITLE:	**Molecular characterization of common animal viral pathogens**
PI:	**Hiep Vu**
DEPT:	Animal Science
Project Biosafety Level:	BSL-2, ABSL-2 (Animal)
NIH Guidelines reference:	III-F-6, III-E, III-E-1, III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-a, III-D-7
PROTOCOL NOTES:	
IRB protocol:	☐Yes ☑No **SROC protocol:** ☐Yes ☑No
IACUC Protocol:	☑Yes ☐No
Objective of Study:	To identify the mechanisms that viruses use to enter susceptible cells, characterize animal immune responses to natural viral infection (or to vaccination), identify viral components capable of inducing immunity and develop safe and effective vaccines against animal viruses.
Changes to the Protocol:	1. Update lab personnel 2. Removed an animal study that will not be pursued.o 3. Edit the influenza virus inventory
Review comments:	None.

NuRamp ID:	1264
Form ID:	**26140**
TITLE:	**Approaches to understand cell-cell signaling**
PI:	**James Checco**
DEPT:	Chemistry
Project Biosafety Level:	BSL-2
NIH Guidelines reference:	III-F-8, C-I, C-II, III-E
PROTOCOL NOTES:	
IRB protocol:	☐Yes ☑No **SROC protocol:** ☐Yes ☑No

IACUC Protocol:	☑Yes ☐No
Objective of Study:	Understand the chemical components and interactions that facilitate cell-to-cell communication. Taking model cell lines or various tissues and extracting their chemical components for analysis, and studying activation of cell surface receptors using biochemical assays.
Changes to the Protocol:	Updated gene list by adding excel file with gene list. New predicted neuropeptide hormone receptors added.
Review comments:	None.

NuRamp ID:	19
Form ID:	**26130**
TITLE:	**Gene regulation by dietary compounds**
PI:	**Janos Zempleni**
DEPT:	Nutrition and Health Sciences
Project Biosafety Level:	BSL-2, ABSL-2 (Animal),
NIH Guidelines reference:	III-F-3, III-F-8, C-I, C-VII, C-VIII, III-E, III-E-3, III-D-3-a, III-D-4-a, III-D-7
PROTOCOL NOTES:	
IRB protocol:	☑Yes ☐No **SROC protocol:** ☐Yes ☑No
IACUC Protocol:	☑Yes ☐No
Objective of Study:	We study the bioavailability and tissues distribution of milk exosomes in mice (and, in the future, humans). We are interested in milk exosomes because of their roles in infant and adult nutrition, and because of their promise for delivering therapeutic cargo to diseased tissues.
Changes to the Protocol:	Section V. Added new information for mouse model Section VI: Added new expression clone
Review comments:	None.

NuRamp ID:	615
Form ID:	**26127**
TITLE:	**Metabolic Engineering and Synthetic Biology**
PI:	**Wei Niu**
DEPT:	Chemical and Biomolecular Engineering
Project Biosafety Level:	BSL-2
NIH Guidelines reference:	III-F-1, III-F-2, III-F-3, III-F-4, III-F-8, C-II, C-III, III-E, III-D-2-a
PROTOCOL NOTES:	
IRB protocol:	☐Yes ☑No **SROC protocol:** ☐Yes ☑No
IACUC Protocol:	☐Yes ☑No
Objective of Study:	Research focuses on changing the metabolic traits of non-pathogenic bacterial and yeast strains by deleting or inserting genetic materials into the strain's genome. The modified strain is cultured and studied for changes in metabolite secretion. The results guide the design of

	subsequent genetic changes in order to optimize the strain's performance in metabolite accumulation.
Changes to the Protocol:	1. Updated personnel 2. Research Description. Added a section on yeast surface display for protein engineering. 3. Recombinant Nucleic Acids. Added recombinant nucleic acids to the vector list and the gene list. 4. Attachment. Added updated list of host, vector, and gene.
Review comments:	None.

5. Notice of Minor Modification Forms Approved:

See attached report for a list of all Minor Modification forms received and approved since the last meeting.

6. Notice of Protocol Annual Updates Received:

See the attached report for a list of all Annual Update forms received and approved since the last meeting.

7. Notice of Protocol Terminations:

NuRamp ID:	**492**
TITLE:	**Quantification of Biochemical Metabolites and Viral Nucleic Acids from Human or Research Animal Tissue Samples**
PI:	**Jessica Calvi**
DEPT:	Athletics
Project Biosafety Level:	**BSL-2**
Project Termination Date:	8/27/2025
PROTOCOL NOTES:	
IRB protocol(s):	☑Yes ☐No **SROC protocol:** ☐Yes ☑No
IACUC Protocol(s):	☐Yes ☑No
Disposition of rDNA and agents:	There are no materials currently with this protocol that need destruction.

NuRamp ID:	**45**
TITLE:	**Using E. coli to express DNA replication proteins**
PI:	**Mark Griep**
DEPT:	Chemistry
Project Biosafety Level:	**BSL-1**
Project Termination Date:	8/14/2025
PROTOCOL NOTES:	
IRB protocol(s):	☐Yes ☑No **SROC protocol:** ☐Yes ☑No
IACUC Protocol(s):	☐Yes ☑No
Disposition of rDNA and agents:	E. coli cells that overproduce various DNA replication proteins were destroyed by autoclaving.

C. Other Business:

1. EHS Report

2. Non-Compliance Reports

II. ADJOURN

Motion: K. Heath
2nd: D. Loy
Time Adjourned: 3:11

IBC Annual Update Form
Approvals since last IBC Meeting

Form ID	Approval Date	IBC Project ID	Project Title	Protocol Status	Form Status	Lead PI	Amendment Needed
UNL-00026190	8/27/2025	UNL-00001327	Design and fabrication of electrochemical peptide-based MRSA sensors	Approved	Approved	Rebecca Lai	**No**
UNL-00026187	8/26/2025	UNL-00000434	Environmental fate of microorganisms originating from livestock production systems	Approved	Approved	Amy Schmidt	**No**
UNL-00026182	8/26/2025	UNL-00001308	Infection, Immunity and Detection of Livestock Pathogens.	Approved	Approved	Dustin Loy	**No**
UNL-00026181	8/26/2025	UNL-00001394	Fostering Student Success in STEM through Early Course-based Undergraduate Research Experiences in Biochemistry	Approved	Approved	Karin van Dijk	**No**
UNL-00026177	8/26/2025	UNL-00000117	Synthetic and Chemical Biology	Approved	Approved	Jiantao Guo	**No**
UNL-00026173	8/26/2025	UNL-00000092	Genetic Manipulation of Mycobacteria	Approved	Approved	Raul Barletta	**No**
UNL-00026172	8/21/2025	UNL-00000728	Carbon nanotube sensors for the detection of nitric oxide	Approved	Approved	Nicole Iverson	**No**
UNL-00026171	8/21/2025	UNL-00001122	Investigations into structure-function studies of metabolic enzymes, and copper-dependent regulation of cell proliferation signaling pathways	Approved	Approved	Jing Zhang	**No**
UNL-00026169	8/13/2025	UNL-00001367	Investigating the regulation of physiological metabolism and the pathogenic mechanism of metabolic diseases.	Approved	Approved	Tatsuya Yamada	**No**
UNL-00026165	8/15/2025	UNL-00001380	Production and storage of African Swine Fever Virus (ASFV) vaccine master seed.	Approved	Approved	Scott McVey	**No**
UNL-00026164	8/7/2025	UNL-00001238	Exosomes and substance use in rat models	Approved	Approved	Rick Bevins	**No**
UNL-00026161	8/25/2025	UNL-00000098	Characterization and Genetic Manipulation of Plant Bacterial Endophytes	Approved	Approved	Raul Barletta	**No**
UNL-00026159	8/26/2025	UNL-00000127	Transformation of Fusarium graminearum	Approved	Approved	Heather Hallen-Adams	**No**
UNL-00026158	8/7/2025	UNL-00000290	Research involving human gut yeasts, including Candida	Approved	Approved	Heather Hallen-Adams	**No**
UNL-00026152	8/7/2025	UNL-00001121	Examining the role of the healthy gastrointestinal microbiome in preventing infection with antibiotic resistant pathogens	Approved	Approved	Jennifer Auchtung	**No**
UNL-00026151	8/6/2025	UNL-00000978	Mechanobiology studies of human and animal cells	Approved	Approved	Ryan Pedrigi	**No**
UNL-00026149	8/6/2025	UNL-00000792	Studies of Host/Microbiome interactions in health and disease	Approved	Approved	Jacques Izard	**No**
UNL-00026148	8/6/2025	UNL-00000164	Genomic Analysis of Fecal Microbiomes From Humans, Poultry, and Canine	Approved	Approved	Andrew Benson	**No**
UNL-00026146	8/6/2025	UNL-00000940	Engineering of photosynthetic and anaerobic bacteria for bioproduct formation.	Approved	Approved	Rajib Saha	**No**
UNL-00026137	8/6/2025	UNL-00000564	Evolutionary and speciation genetics using Drosophila as a model system.	Approved	Approved	Colin Meiklejohn	**No**

Minor Modification Forms Approved since Last IBC Meeting

Form ID	IBC Project ID	Approval Date	ProjectTitle	Protocol Status	Form Status	Lead PI	Form Changes
UNL-00001483	UNL-00001483	8/27/2025	The Impact of Cancer Treatment on Lymphatic Vessel Regeneration and Remodeling	Approved	Approved	Mohammad Razavi	Personnel
UNL-00000619	UNL-00000619	8/27/2025	Infectious Diseases Vaccine Development	Approved	Approved	Eric Weaver	Personnel
UNL-00001350	UNL-00001350	8/13/2025	Optimized Molecular and RNAi-Based Approaches for Detecting Arthropod-Borne Pathogens and Silencing Target Transcripts in Insects	Approved	Approved	Leslie Rault	Personnel
UNL-00001350	UNL-00001350	8/8/2025	Optimized Molecular and RNAi-Based Approaches for Detecting Arthropod-Borne Pathogens and Silencing Target Transcripts in Insects	Approved	Approved	Leslie Rault	Personnel
UNL-00001450	UNL-00001450	8/8/2025	Understanding the Cognitive and Brain Health in Relation to Diet and Dietary Interventions	Approved	Approved	Aron Keith Barbey	Personnel

EHS/Biosafety Officer Report for IBC meeting on 9/8/2025

Biosafety Recurring Audits Since last meeting:

BSL-2	BSL-1
• Ramer-Tait (ABSL-2)	• Harveson, Robert • Isom, Loren • Yates, Dustin

Pre-approval Audits:

- None

BSL-3 Lab Updates

- SA Registration updates
- Facility updates

Post approval Monitoring since Last IBC meeting:

- None

Other Activities: *(Regulation updates, news, new/revised policies, etc.)*

- Helikar Lab update